Literature DB >> 21796625

Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.

Su-Ni Tang1, Junsheng Fu, Dara Nall, Mariana Rodova, Sharmila Shankar, Rakesh K Srivastava.   

Abstract

Activation of the sonic hedgehog (SHh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). The objectives of this study were to examine the molecular mechanisms by which (-)-epigallocatechin-3-gallate (EGCG), an active compound in green tea, inhibits self-renewal capacity of pancreatic CSCs and synergizes with quercetin, a major polyphenol and flavonoid commonly detected in many fruits and vegetables. Our data demonstrated that EGCG inhibited the expression of pluripotency maintaining transcription factors (Nanog, c-Myc and Oct-4) and self-renewal capacity of pancreatic CSCs. Inhibition of Nanog by shRNA enhanced the inhibitory effects of EGCG on self-renewal capacity of CSCs. EGCG inhibited cell proliferation and induced apoptosis by inhibiting the expression of Bcl-2 and XIAP and activating caspase-3. Interestingly, EGCG also inhibited the components of SHh pathway (smoothened, patched, Gli1 and Gli2) and Gli transcriptional activity. Furthermore, EGCG inhibited EMT by inhibiting the expression of Snail, Slug and ZEB1, and TCF/LEF transcriptional activity, which correlated with significantly reduced CSC's migration and invasion, suggesting the blockade of signaling involved in early metastasis. Furthermore, combination of quercetin with EGCG had synergistic inhibitory effects on self-renewal capacity of CSCs through attenuation of TCF/LEF and Gli activities. Since aberrant SHh signaling occurs in pancreatic tumorigenesis, therapeutics that target SHh pathway may improve the outcomes of patients with pancreatic cancer by targeting CSCs.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796625      PMCID: PMC3480310          DOI: 10.1002/ijc.26323

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Dietary flavonoids and the risk of lung cancer and other malignant neoplasms.

Authors:  P Knekt; R Järvinen; R Seppänen; M Hellövaara; L Teppo; E Pukkala; A Aromaa
Journal:  Am J Epidemiol       Date:  1997-08-01       Impact factor: 4.897

Review 4.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

Authors:  R K Srivastava
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

5.  Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors.

Authors:  Christina E Hoei-Hansen; John E Nielsen; Kristian Almstrup; Si Brask Sonne; Niels Graem; Niels E Skakkebaek; Henrik Leffers; Ewa Rajpert-De Meyts
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

6.  The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.

Authors:  Su-Ni Tang; Chandan Singh; Dara Nall; Daniel Meeker; Sharmila Shankar; Rakesh K Srivastava
Journal:  J Mol Signal       Date:  2010-08-18

Review 7.  Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs.

Authors:  Vasundhra Kashyap; Naira C Rezende; Kymora B Scotland; Sebastian M Shaffer; Jenny Liao Persson; Lorraine J Gudas; Nigel P Mongan
Journal:  Stem Cells Dev       Date:  2009-09       Impact factor: 3.272

8.  Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

Authors:  Maria-Theresa Mueller; Patrick C Hermann; Juliane Witthauer; Belen Rubio-Viqueira; Simon F Leicht; Stephan Huber; Joachim W Ellwart; Mona Mustafa; Peter Bartenstein; Jan G D'Haese; Michael H Schoenberg; Frank Berger; Karl-Walter Jauch; Manuel Hidalgo; Christopher Heeschen
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

9.  Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells.

Authors:  Rakesh K Srivastava; Su-Ni Tang; Wenyu Zhu; Daniel Meeker; Sharmila Shankar
Journal:  Front Biosci (Elite Ed)       Date:  2011-01-01

Review 10.  Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis.

Authors:  Maria-Theresa Mueller; Patrick C Hermann; Christopher Heeschen
Journal:  Front Biosci (Elite Ed)       Date:  2010-01-01
View more
  86 in total

1.  Sulforaphane as a Promising Natural Molecule for Cancer Prevention and Treatment.

Authors:  Osama A Elkashty; Simon D Tran
Journal:  Curr Med Sci       Date:  2021-04-20

2.  Ski modulate the characteristics of pancreatic cancer stem cells via regulating sonic hedgehog signaling pathway.

Authors:  Libin Song; Xiangyuan Chen; Song Gao; Chenyue Zhang; Chao Qu; Peng Wang; Luming Liu
Journal:  Tumour Biol       Date:  2016-10-12

3.  SOX9 inhibits β-TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties.

Authors:  Wentao Deng; Daniel B Vanderbilt; Chen-Chung Lin; Karen H Martin; Kathleen M Brundage; J Michael Ruppert
Journal:  J Cell Sci       Date:  2015-01-27       Impact factor: 5.285

4.  CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide.

Authors:  Sulagna Banerjee; Alice Nomura; Veena Sangwan; Rohit Chugh; Vikas Dudeja; Selwyn M Vickers; Ashok Saluja
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

Review 5.  Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer.

Authors:  Hideya Onishi; Mitsuo Katano
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 6.  New Opportunities and Challenges to Defeat Cancer Stem Cells.

Authors:  Erika K Ramos; Andrew D Hoffmann; Stanton L Gerson; Huiping Liu
Journal:  Trends Cancer       Date:  2017-09-21

Review 7.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

Review 8.  New insights into pancreatic cancer stem cells.

Authors:  Chinthalapally V Rao; Altaf Mohammed
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

9.  (-)-Epigallocatechin-3-gallate inhibits nasopharyngeal cancer stem cell self-renewal and migration and reverses the epithelial-mesenchymal transition via NF-κB p65 inactivation.

Authors:  Ya-Jun Li; Shun-Long Wu; Song-Mei Lu; Fang Chen; Ying Guo; Sheng-Min Gan; Yan-Long Shi; Shuang Liu; Shao-Lin Li
Journal:  Tumour Biol       Date:  2014-12-07

10.  HepG2 cells acquire stem cell-like characteristics after immune cell stimulation.

Authors:  Hang Wang; Miqing Yang; Ling Lin; Hongzhen Ren; Chaotong Lin; Suling Lin; Guoying Shen; Binfeng Ji; Chun Meng
Journal:  Cell Oncol (Dordr)       Date:  2015-12-09       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.